Dynamic-I

INTERVENTION: Group I. One daily intramuscular application of 10x106 UI of the product under study for 2 consecutive days. Group II. One daily intramuscular application of 5x106 UI of the product under study for 4 consecutive days. Group III. One daily intramuscular application of 3x106 UI of the product under study for 7 consecutive days. The three groups will thus receive practically the same weekly dosage of 20x106 UI. Interferon‐alpha recombinant human alpha‐2b interferon CONDITION: Acuminate Condyloma Condylomata Acuminata PRIMARY OUTCOME: Beta‐2 microglobulin level, measuring time: before and after treatment. 2.5 oligoadenylate synthetase level, measuring time: before and after treatment. SECONDARY OUTCOME: Size of lesions (greater and lesser diameters), measuring time: before and after treatment. Number of lesions, measuring time: before and after treatment. Need for other conventional treatments, measuring time: before and after treatment. INCLUSION CRITERIA: Clinical and histological diagnosis positive to Acuminate Condyloma by papilloma virus. Patients of both sexes with Acuminate Condyloma lesions in external genitals, perianal region, and inner thighs. Patients aged 18 to 60. No topical or systemic treatment with IFN or any other antiviral drug one month before inclusion in the study. Reproductive‐age women using any non‐hormonal contraceptive. Patient's consent in writing to participate in the study.